A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of varying degrees of impaired
hepatic function (by Child-Pugh classification) on the pharmacokinetics (PK) of ABL001 after
a single oral dose.